Ocular Hypertension Market is segmented By Type of Disease (Intraocular Hypertension, Glaucoma), By End-use (Hospitals, Specialty Clinics, Pharmacies), By Route of Admini ....
Market Size in USD
CAGR4.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 4.1% |
Market Concentration | Medium |
Major Players | Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Aerie Pharmaceuticals, Santen Pharmaceuticals |
The Global Ocular Hypertension Market is estimated to be valued at USD 3.9 billion in 2024 and is expected to reach USD 4.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.1% from 2024 to 2031. The aging global population is driving the need for early diagnosis and treatment of glaucoma and other ocular conditions. As awareness about eye care increases, more individuals are getting their eyes regularly monitored for ocular hypertension.
The ocular hypertension market is expected to witness positive growth over the forecast period due to rising prevalence of glaucoma worldwide. Increasing demand for early screening and diagnosis is expected to boost market growth. Furthermore, various players in this market are involved in new product launches and regulatory approvals, which is further expected to augment the market expansion. However, high cost of ocular surgery and eye treatments is a major factor restraining the market growth.